Fusion Antibodies News
R&D update: Mammalian Display service
Fusion Antibodies release an R&D update: Mammalian Display service OptiMAL®
One size fits all: A bispecific antigen toolkit for antibody discovery and screening
Fusion Antibodies have harnessed a bispecific antigen toolkit for antibody discovery and screening.
Appointment of Chief Executive Officer
Fusion Antibodies plc announces the appointment of Dr Adrian Kinkaid as Chief Executive Officer.
Fusion Antibodies plc Announces Formation of New Scientific Advisory Panel
World-renowned experts in the fields of antibody engineering Matthew Baker Ph.D., Professor Terry Rabbitts, and Professor Charlotte Deane to join Fusion Antibodies Scientific Advisory Panel
Omicron introduced to Fusion Antibodies R&D Catalogue
Fusion Antibodies has decided to include Omicron RBD, alongside the alpha, beta, gamma and delta+ RBD variants, in its development programme with the aim of producing virus-neutralising antibodies.
Fusion Antibodies RAMPs Up Collaboration Success
New $1.83 million R&D project win for Fusion Antibodies reinforces its position as one of the leading providers of early-stage antibody discovery and engineering services.
Fusion Antibodies partners with Eurofins Discovery to support innovative preclinical drug discovery research
Fusion Antibodies and Eurofins Discovery sign co-marketing agreement to support timely and cost-effective development of innovative products for the benefit of global healthcare
Supporting Indian Biotherapeutic Companies with Antibody Development
Fusion Antibodies, pre-clinical antibody discovery and development experts and BioTickle, their exclusive distributor in India, are providing local biopharmaceutical organisations with access to invaluable unique biopharmaceutical development capabilities.
Fusion Antibodies proud to support ‘State of the Art’ project
NI Science Festival, in conjunction with Linen Biennale recently rolled out the virtual red carpet to premier Dr Anthony O’Kane’s ‘Translating Linen.’
Fusion Antibodies awarded Platinum Level Innovator Status by Innovate NI
Fusion Antibodies is delighted to be recognised as a Platinum Level Innovator in the Innovate NI Innovation Accreditation programme from the Department for the Economy.
Fusion Antibodies and Queen’s University Belfast Receive Grant to Boost R&D for COVID-19 Antibodies
Fusion Antibodies and Queen’s University Belfast Receive £453,000 grant from Invest Northern Ireland to Boost Research and Development for COVID-19 Antibodies
200 Reasons to Celebrate!
Fusion Antibodies are celebrating their 200th Antibody Humanization project, cementing our place as a leading CRO in antibody engineering services.